<code id='970EEBC4B8'></code><style id='970EEBC4B8'></style>
    • <acronym id='970EEBC4B8'></acronym>
      <center id='970EEBC4B8'><center id='970EEBC4B8'><tfoot id='970EEBC4B8'></tfoot></center><abbr id='970EEBC4B8'><dir id='970EEBC4B8'><tfoot id='970EEBC4B8'></tfoot><noframes id='970EEBC4B8'>

    • <optgroup id='970EEBC4B8'><strike id='970EEBC4B8'><sup id='970EEBC4B8'></sup></strike><code id='970EEBC4B8'></code></optgroup>
        1. <b id='970EEBC4B8'><label id='970EEBC4B8'><select id='970EEBC4B8'><dt id='970EEBC4B8'><span id='970EEBC4B8'></span></dt></select></label></b><u id='970EEBC4B8'></u>
          <i id='970EEBC4B8'><strike id='970EEBC4B8'><tt id='970EEBC4B8'><pre id='970EEBC4B8'></pre></tt></strike></i>

          explore

          explore

          author:focus    Page View:713
          Nasdaq
          Mario Tama/Getty Images

          Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year.

          The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.

          advertisement

          The biotech had begun planning for an IPO last year, STAT reported in June 2022. It raised $112 million in what would turn out to be a crossover round last October.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Roche’s Alnylam deal shows drug firms interested in heart drugs
          Roche’s Alnylam deal shows drug firms interested in heart drugs

          AdobeRoche’sannouncementMondaythatitwouldpay$310millionforrightstoahypertensiontreatment,zilebesiran

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          CDC Director Mandy Cohen on transparency, trust, and health

          CDCDirectorMandyCohenCliffOwen/APThenewdirectoroftheCentersforDiseaseControlandPrevention,MandyCohen